Mosunetuzumab Interactions
There are 247 drugs known to interact with mosunetuzumab. Of the total drug interactions, 34 are major, 198 are moderate, and 15 are minor.
Medications known to interact with mosunetuzumab
Note: Showing generic names only.
A
- abrocitinib
- adalimumab
- ado-trastuzumab emtansine
- alefacept
- alemtuzumab
- alfentanil
- allogeneic processed thymus tissue
- aminophylline
- amiodarone
- anakinra
- apixaban
- astemizole
- atezolizumab
- atomoxetine
- atorvastatin
- auranofin
- aurothioglucose
- avelumab
- axicabtagene ciloleucel
- azathioprine
B
- baricitinib
- bcg
- belimumab
- benznidazole
- bifidobacterium infantis
- bifidobacterium longum
- bortezomib
- brentuximab
- brewer's yeast
- brexpiprazole
- brexucabtagene autoleucel
C
- cabazitaxel
- canakinumab
- carbamazepine
- carboplatin
- carfilzomib
- cemiplimab
- cerivastatin
- certolizumab
- chloramphenicol
- chloramphenicol ophthalmic
- chloramphenicol otic
- chloroquine
- ciltacabtagene autoleucel
- cinoxacin
- ciprofloxacin
- cisapride
- cisplatin
- cladribine
- clozapine
- colchicine
- cosibelimab
- crizotinib
- cyclosporine
D
- dapsone
- deferiprone
- delafloxacin
- denosumab
- deucravacitinib
- dicumarol
- didanosine
- dihydroergotamine
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- disopyramide
- disulfiram
- docetaxel
- dostarlimab
- dronedarone
- durvalumab
- dyphylline
E
- efalizumab
- efbemalenograstim alfa
- eflapegrastim
- eliglustat
- elotuzumab
- elranatamab
- enfortumab vedotin
- enoxacin
- ergotamine
- eribulin
- etanercept
- ethambutol
- ethionamide
- etoposide
- etrasimod
- etravirine
- everolimus
- ezogabine
F
G
H
I
- idecabtagene vicleucel
- infliximab
- interferon alfa-2a
- interferon alfa-2b
- interferon alfa-n1
- interferon alfacon-1
- iodoquinol
- ipilimumab
- isoniazid
- ixabepilone
- ixazomib
L
- lactobacillus acidophilus
- lactobacillus reuteri
- lactobacillus rhamnosus
- lactobacillus rhamnosus gg
- leflunomide
- levodopa
- levofloxacin
- lidocaine
- linezolid
- lisocabtagene maraleucel
- lomefloxacin
- loncastuximab tesirine
- lovastatin
- lurbinectedin
M
- mephenytoin
- mesoridazine
- methadone
- metronidazole
- mexiletine
- mirvetuximab soravtansine
- monomethyl fumarate
- moxifloxacin
N
- nadofaragene firadenovec
- nalidixic acid
- natalizumab
- naxitamab
- nelarabine
- niraparib
- nitrofurantoin
- nivolumab
- norfloxacin
O
P
- paclitaxel
- paclitaxel protein-bound
- palifermin
- pegfilgrastim
- peginterferon alfa-2a
- peginterferon alfa-2b
- pembrolizumab
- penpulimab
- phenobarbital
- phenytoin
- pimozide
- pitavastatin
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pravastatin
- primidone
- procainamide
- propafenone
Q
R
- radium 223 dichloride
- red yeast rice
- repotrectinib
- retifanlimab
- rilonacept
- ritlecitinib
- rivaroxaban
- roflumilast
- ropeginterferon alfa-2b
- rosuvastatin
- ruxolitinib topical
S
- saccharomyces boulardii lyo
- samarium sm 153 lexidronam
- sargramostim
- secnidazole
- selinexor
- simvastatin
- siponimod
- sipuleucel-T
- sirolimus
- sodium phosphate p32
- sparfloxacin
- stavudine
- streptococcus salivarius
- strontium-89 chloride
- sunitinib
T
- tacrolimus
- tacrolimus topical
- talquetamab
- tarlatamab
- tbo-filgrastim
- teclistamab
- telbivudine
- telisotuzumab vedotin
- temsirolimus
- teniposide
- terfenadine
- teriflunomide
- thalidomide
- theophylline
- thioridazine
- tinidazole
- tisagenlecleucel
- tislelizumab
- tisotumab vedotin
- tizanidine
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- trabectedin
- tremelimumab
- trovafloxacin
U
V
W
Z
Report options
QR code containing a link to this page
More about mosunetuzumab
- mosunetuzumab consumer information
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
